Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes | Zendy

Katherine Garlo | Zendy; William B. White | Zendy; George L. Bakris | Zendy; Faı̈ez Zannad | Zendy; Craig Wilson | Zendy; Stuart Kupfer | Zendy; Muthiah Vaduganathan | Zendy; David A. Morrow | Zendy; Christopher P. Can | Zendy; David M. Charytan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes

Author(s) -

Katherine Garlo,

William B. White,

George L. Bakris,

Faı̈ez Zannad,

Craig Wilson,

Stuart Kupfer,

Muthiah Vaduganathan,

David A. Morrow,

Christopher P. Can,

David M. Charytan

Publication year - 2018

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.05280517

Subject(s) - medicine , hazard ratio , renal function , cystatin c , kidney disease , alogliptin , confidence interval , proportional hazards model , type 2 diabetes , dialysis , diabetes mellitus , endocrinology , dipeptidyl peptidase 4

Biomarkers may improve identification of individuals at risk of eGFR decline who may benefit from intervention or dialysis planning. However, available biomarkers remain incompletely validated for risk stratification and prediction modeling.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research